Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 163 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (PBO) Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03370133
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Ustekinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Extension in AS: Sustainability of Benefits, Safety and Tolerability

NCT01863732
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo (Pbo)
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

NCT03288454
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Apixaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder

NCT00389493
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Risperidone, Exposure/ritual prevention therapy (EX/RP), Placebo
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 28, 2026, 11:02 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

NCT06222268
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis Use
Interventions
Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only, THC:CBD 1:1
Drug
Lead sponsor
Leslie Lundahl
Other
Eligibility
18 Years to 60 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX

NCT01855789
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab (TCZ), Methotrexate (MTX), Placebo (PBO)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
155
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

NCT03428217
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
CB-839, Cabozantinib, Placebo
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

NCT04659161
View directory record Official record
Conditions
Schizophrenia, Schizophrenia; Psychosis
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Little Rock, Arkansas • Bellflower, California • Culver City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

NCT00806026
View directory record Official record
Conditions
Idiopathic Restless Legs Syndrome
Interventions
placebo and pregabalin, pramipexol, Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Jasper, Alabama • Tuscaloosa, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

NCT03928743
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

NCT01490450
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo matching BMS-945429, BMS-945429
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 28, 2026, 11:02 PM EDT
Recruiting Phase 1 Interventional

Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder

NCT06538558
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Tezampanel, Placebo
Drug
Lead sponsor
Proniras Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

NCT04405739
View directory record Official record
Conditions
SARS-CoV 2
Interventions
EIDD-2801, Placebo
Drug
Lead sponsor
Ridgeback Biotherapeutics, LP
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Los Angeles, California • Chicago, Illinois • Oak Lawn, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 28, 2026, 11:02 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

NCT03712787
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tilavonemab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
57 Years to 88 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
32
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 28, 2026, 11:02 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553
View directory record Official record
Conditions
Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
54
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

NCT04632381
View directory record Official record
Conditions
Corona Virus Infection
Interventions
Zotatifin, Placebo
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Anniston, Alabama • Cullman, Alabama • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

NCT04046939
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 74 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
36
States / cities
Los Angeles, California • Mission Viejo, California • Westminster, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

NCT04677504
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Atezolizumab, Bevacizumab, Placebo, Cisplatin, Gemcitabine
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

NCT05066672
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
NV-5138, matched placebo
Drug
Lead sponsor
Navitor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana

NCT00743145
View directory record Official record
Conditions
Marijuana Smoking
Interventions
Inactive Marijuana (0% THC), Active Marijuana (5.5% THC), Active Marijuana (6.2% THC), Naltrexone, Placebo naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Results available

Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

NCT04411914
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Clavulanic Acid, Placebo
Drug · Other
Lead sponsor
Temple University
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT04294667
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DZP, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
16 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

PRO 140 by IV Administration in Adults With HIV-1 Infection

NCT00613379
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140, Placebo
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 28, 2026, 11:02 PM EDT